BioWorld

Oct. 7, 2008

It's Official: Lilly Offers $70 per Share for ImClone in $6.5B Deal

Indianapolis-based Eli Lilly and Co. officially emerged Monday as the $70-per-share bidder for ImClone Systems Inc., affirming last week's speculation on the Street, as it aims to pick up a pipeline that includes marketed EGFR inhibitor Erbitux and three late-stage oncology programs. (BioWorld Today) Read More

France Missing the Boat as Biotech Moves Downstream

Biolex Raises $60M, Buys Rest of Locteron Rights from OctoPlus

CombinatorX Shares Spiral as Pain Study Misses Mark

Salix's Rifaximin IBS Data Bring Strong Share Bump

Cortex Rises on Good Data from Respiratory Study

Dendreon Soars on Provenge Interim Data, but BLA to Wait

OSI, Genentech Slump on Avastin-Tarceva Miss

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for July 18, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for July 18, 2025.

Biocon wins first FDA interchangeable label of Novolog biosimilar

BioWorld

The U.S. FDA on July 15 cleared Biocon Biologics Ltd.’s Kirsty (insulin aspart-xjhz) as the first and only interchangeable biosimilar product referencing Novo...

Adcom agrees with FDA: Otsuka’s PTSD treatment needs more study

BioWorld

In a 10-1 vote, the U.S. FDA’s Psychopharmacologic Drugs Advisory Committee said Otsuka Pharmaceutical Co. Ltd.’s studies of its combination post-traumatic stress...

Proteomics finds surprise commonalities as well as differences in neurodegenerative diseases

BioWorld

The switch will be flicked today to make the world’s largest dementia-related proteomics dataset freely available to researchers, at the same time as members of...